A Phase IIb Randomized, Double-Blind, Placebo-Controlled Human Trial of the Lipolytic Oligopeptide AOD9604 for the Management of Overweight and Obesity Profiles

Journal Context: Obesity Research / Nature Publishing Group | Identifiers: DOI: 10.1038/oby.2006.27 / PMID: 16560124

Principal Investigators: Heffernan, M., Sum, C. Z., Thorburn, A. W., & Ng, F. M. (Department of Biochemistry and Molecular Biology, Monash University, Australia / Metabolic Pharmaceuticals Ltd.)

Methodology: A multi-center Phase IIb human clinical trial enrolling 300 obese adult participants. Subjects were randomized to receive either a daily oral placebo or varying micro-gram doses of the synthetic 176-191 fragment over a continuous 12-week protocol to measure changes in body weight, waist circumference, and oral glucose tolerance.

Key Findings: Daily administration of the 176-191 fragment resulted in a statistically significant, progressive reduction in total body weight and abdominal fat-mass indices compared to the placebo cohort. Crucially, unlike raw human growth hormone, the active fragment induced no adverse alterations in glucose tolerance, fasting insulin lines, or IGF-1 levels, confirming its status as a highly selective fat-burning agent that completely avoids the risk of inducing diabetes.